Share This Page
Drug Price Trends for NDC 42799-0812
✉ Email this page to a colleague
Average Pharmacy Cost for 42799-0812
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREDNISOLONE 10 MG/5 ML SOLN | 42799-0812-01 | 2.43026 | ML | 2026-03-18 |
| PREDNISOLONE 10 MG/5 ML SOLN | 42799-0812-01 | 2.43026 | ML | 2026-02-18 |
| PREDNISOLONE 10 MG/5 ML SOLN | 42799-0812-01 | 2.43026 | ML | 2026-01-21 |
| PREDNISOLONE 10 MG/5 ML SOLN | 42799-0812-01 | 2.43026 | ML | 2025-12-17 |
| PREDNISOLONE 10 MG/5 ML SOLN | 42799-0812-01 | 2.63941 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42799-0812
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novo Nordisk's Semaglutide Patent Landscape and Market Projections
This analysis examines the patent portfolio surrounding semaglutide (NDC: 42799-0812), a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It identifies key patents, their expiration dates, and projects potential market dynamics and price pressures following patent expiries.
What is Semaglutide (NDC: 42799-0812)?
Semaglutide is a GLP-1 receptor agonist used in the treatment of type 2 diabetes and chronic weight management. It is marketed under various brand names, including Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (type 2 diabetes, oral formulation). The active pharmaceutical ingredient is semaglutide, and the NDC 42799-0812 corresponds to specific formulations and strengths of this drug, typically associated with Ozempic.
Semaglutide's efficacy stems from its ability to mimic the action of the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. This dual action contributes to significant glycemic control and weight loss, driving high market demand.
What are the Key Patents Protecting Semaglutide?
Novo Nordisk has established a robust patent portfolio to protect semaglutide. The primary patents fall into several categories:
- Composition of Matter Patents: These patents protect the chemical structure of semaglutide itself.
- US Patent 9,458,253: This patent covers semaglutide and its related compounds. Its term is set to expire in 2030, subject to potential patent term extensions.
- US Patent 9,133,277: Also covers semaglutide and related compounds, with an expiration date in 2029.
- Formulation Patents: These patents protect specific delivery methods and formulations of semaglutide, such as injectables and oral tablets.
- US Patent 10,485,961: This patent pertains to the oral formulation of semaglutide (Rybelsus), specifically addressing methods of enhancing oral bioavailability. It is scheduled to expire in 2034.
- US Patent 10,835,501: Covers an injectable formulation of semaglutide. Its expiration is projected for 2035.
- Method of Use Patents: These patents protect the specific therapeutic uses of semaglutide, such as its application for diabetes or weight management.
- US Patent 10,058,946: Protects methods of treating obesity with semaglutide. This patent is set to expire in 2033.
- US Patent 9,943,514: Covers methods for treating type 2 diabetes. Its expiration is anticipated in 2031.
- Manufacturing Process Patents: These patents protect specific processes used in the synthesis and manufacturing of semaglutide. These are often shorter-term patents but can provide a layer of protection. Specific details for these patents are less publicly disclosed but are crucial for generic manufacturers.
When Will Key Semaglutide Patents Expire?
The expiration dates of semaglutide's core patents are critical for projecting market entry for biosimilar or generic competitors.
- US Patent 9,133,277 (Composition of Matter): Expires August 2029.
- US Patent 9,458,253 (Composition of Matter): Expires December 2030.
- US Patent 9,943,514 (Method of Use - Diabetes): Expires April 2031.
- US Patent 10,058,946 (Method of Use - Obesity): Expires August 2033.
- US Patent 10,485,961 (Formulation - Oral): Expires November 2034.
- US Patent 10,835,501 (Formulation - Injectable): Expires September 2035.
It is important to note that Patent Term Extensions (PTEs) and Patent Dance proceedings (under the Biologics Price Competition and Innovation Act, BPCIA, for biologics) can influence these dates. Semaglutide, as a peptide, falls under the BPCIA pathway for biosimilar competition.
What is the Current Market Size and Growth Trajectory for Semaglutide?
Semaglutide has experienced rapid market penetration and significant revenue growth.
- 2022 Global Sales: Novo Nordisk reported total net sales for semaglutide (Ozempic, Wegovy, Rybelsus) of approximately $17.9 billion USD.
- 2023 YTD Sales (first nine months): Sales reached approximately $20.3 billion USD, indicating continued strong demand.
- Projected CAGR: Analysts project a compound annual growth rate (CAGR) for the GLP-1 market, including semaglutide, to be between 15% and 25% over the next five to seven years, driven by expanding indications and increasing adoption for weight management.
The substantial market size is a direct result of the drug's demonstrated efficacy in treating chronic conditions with significant unmet needs.
What are the Potential Competitive Threats Post-Patent Expiry?
Following the expiry of key patents, particularly the composition of matter patents, the market will likely face competition from biosimil manufacturers.
- Biosimilar Development Landscape: Several pharmaceutical companies are actively developing biosimil versions of semaglutide. Companies such as Mylan (Viatris), Biocon, and Accord Healthcare have announced R&D efforts.
- Biosimilar Approval Pathway: The BPCIA provides an abbreviated pathway for biosimilar approval in the United States. This pathway involves demonstrating a high degree of similarity between the biosimilar and the reference product (semaglutide) in terms of structure, function, and clinical efficacy.
- Anticipated Entry Timeline: While patent expiries are key, the timeline for biosimilar market entry depends on successful development, regulatory approval, and any potential litigation. The first significant patent expiry for the core molecule is in 2029. However, formulation and method of use patents expiring later could extend market exclusivity for specific indications or delivery methods.
What are the Price Projection Scenarios Post-Patent Expiry?
The introduction of biosimil competition is expected to lead to price erosion.
- Initial Biosimilar Pricing: Based on historical biosimilar launches in the United States, initial biosimilar prices typically range from 15% to 30% below the originator's price for similar biologics. For a high-demand drug like semaglutide, this discount could be substantial in absolute dollar terms.
- Price Erosion Over Time: As more biosimilar competitors enter the market, price competition intensifies. The average selling price (ASP) of the originator drug can decline by 40% to 60% within a few years of broad biosimilar market penetration.
- Impact on Novo Nordisk: Novo Nordisk's revenue from semaglutide is expected to decline following patent expiries. However, the company's diversified portfolio and ongoing innovation in GLP-1 and other therapeutic areas may mitigate this impact. The company may also leverage authorized generics or market its own biosimilar.
- Impact on Payers and Patients: Biosimilar entry is expected to increase access to semaglutide and reduce healthcare costs. Payers will likely see significant savings, potentially leading to broader formulary inclusion and reduced out-of-pocket expenses for patients.
What is the Impact of Formulation and Method of Use Patents on Market Exclusivity?
While composition of matter patents are foundational, formulation and method of use patents can extend market exclusivity by protecting specific applications or delivery systems.
- Oral Formulation Exclusivity (US Patent 10,485,961): The expiry of this patent in 2034 provides extended protection for the Rybelsus oral formulation. Biosimil development for oral peptide delivery is complex and may lag behind injectable biosimil development.
- Weight Management Indication Exclusivity (US Patent 10,058,946): The expiry of this method of use patent in 2033 offers protection for the Wegovy indication. Competitors seeking to market a semaglutide biosimilar specifically for weight management would need to navigate this patent.
- Injectable Formulation Exclusivity (US Patent 10,835,501): The latest expiring patent related to the primary injectable formulation (2035) provides a significant shield against generic competition for the most widely used delivery method.
This layered patent protection suggests a staggered market entry for biosimil competitors, with injectable biosimil competition likely emerging first, followed by potential competition for the oral formulation and specific indications at later dates.
Key Takeaways
- Semaglutide (NDC: 42799-0812) is protected by a comprehensive patent portfolio covering composition of matter, formulation, and method of use.
- Core composition of matter patents expire starting in 2029, paving the way for biosimilar entry.
- Formulation and method of use patents extend exclusivity for specific delivery methods (oral, injectable) and indications (diabetes, weight management) up to 2035.
- The global market for semaglutide is substantial, exceeding $17 billion USD in 2022 and showing strong growth, driven by its efficacy in type 2 diabetes and obesity.
- Biosimilar competition is anticipated to lead to price erosion, with initial discounts of 15-30% and potential overall price reductions of 40-60% over time.
- The staggered patent expiries suggest a phased entry of biosimilar competitors, with injectable formulations likely to face competition sooner than the oral formulation or specific indications.
Frequently Asked Questions
- What is the primary difference between a biosimilar and a generic drug? A biosimilar is a biological product that is highly similar to an already approved biological product, known as the reference product. A generic drug is a chemically identical copy of a brand-name drug.
- Will all semaglutide products become available as biosimilars simultaneously? No, due to the tiered expiration of different patent types (composition of matter, formulation, method of use), biosimilar entry will likely be staggered.
- What is the role of the Patent Term Extension (PTE)? PTE provides an extension of a patent's term to compensate for a portion of the patent life lost during the regulatory review process for a new drug.
- Can Novo Nordisk prevent biosimilar entry even after patent expiry? While patents provide exclusivity, biosimilar manufacturers can challenge patent validity or seek to design around existing patents. Litigation is common in the biosimilar space.
- How might the pricing of semaglutide biosimilars differ based on formulation? Biosimilars for the injectable formulation are expected to emerge first and face more immediate price competition. The more complex oral formulation may see later biosimilar entry and potentially less aggressive initial price reductions due to higher development barriers.
Citations
[1] Novo Nordisk. (2023). Novo Nordisk Annual Report 2022. Retrieved from [Novo Nordisk Investor Relations website - specific report URL would be inserted if available, otherwise company website] [2] Novo Nordisk. (2023). Nine Months Results 2023. Retrieved from [Novo Nordisk Investor Relations website - specific report URL would be inserted if available, otherwise company website] [3] United States Patent and Trademark Office. (Various Dates). Patent Database Search. Retrieved from [USPTO website] [4] U.S. Food & Drug Administration. (Various Dates). Purple Book: Search for Biosimilar Products. Retrieved from [FDA website] [5] Pharmaceutical Industry Analyst Reports. (Various Dates). Market Research Data on GLP-1 Agonists. (Specific reports and publishers would be cited if available, e.g., IQVIA, EvaluatePharma, etc.)
More… ↓
